Strategies to Augment Natural Killer (NK) Cell Activity against Solid Tumors
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Strategies to Augment Natural Killer (NK) Cell Activity against Solid Tumors
Authors
Keywords
-
Journal
Cancers
Volume 11, Issue 7, Pages 1040
Publisher
MDPI AG
Online
2019-07-24
DOI
10.3390/cancers11071040
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting NKG2A to elucidate natural killer cell ontogenesis and to develop novel immune-therapeutic strategies in cancer therapy
- (2019) Elisa Zaghi et al. JOURNAL OF LEUKOCYTE BIOLOGY
- De novo design of potent and selective mimics of IL-2 and IL-15
- (2019) Daniel-Adriano Silva et al. NATURE
- NK cells specifically TCR-dressed to kill cancer cells
- (2019) Nadia Mensali et al. EBioMedicine
- IL-15 by continuous i.v. infusion to adult patients with solid tumors in a Phase I trial induced dramatic NK cell subset expansion
- (2019) Kevin C Conlon et al. CLINICAL CANCER RESEARCH
- Engineering antigen‐specific NK cell lines against the melanoma‐associated antigen tyrosinase via TCR gene transfer
- (2019) Ayhan Parlar et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells
- (2019) Takahiro Kamiya et al. JOURNAL OF CLINICAL INVESTIGATION
- A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors
- (2019) Salah-Eddine Bentebibel et al. Cancer Discovery
- Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity
- (2019) Laurent Gauthier et al. CELL
- First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
- (2018) Rizwan Romee et al. BLOOD
- Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity
- (2018) Ye Li et al. Cell Stem Cell
- Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML
- (2018) Andreas T. Björklund et al. CLINICAL CANCER RESEARCH
- Phase I clinical trial of adoptive transfer of expanded natural killer cells in combination with IgG1 antibody in patients with gastric or colorectal cancer
- (2018) Takeshi Ishikawa et al. INTERNATIONAL JOURNAL OF CANCER
- NKG2D Immunoligand rG7S-MICA Enhances NK Cell-mediated Immunosurveillance in Colorectal Carcinoma
- (2018) Tong Wang et al. JOURNAL OF IMMUNOTHERAPY
- ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial
- (2018) John M Wrangle et al. LANCET ONCOLOGY
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies
- (2018) Norbert Vey et al. Oncotarget
- Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37
- (2018) Dhifaf Sarhan et al. Cancer Immunology Research
- A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma
- (2018) Wing Keung Chan et al. Cancer Immunology Research
- The Role of CXC Chemokine Receptors 1–4 on Immune Cells in the Tumor Microenvironment
- (2018) Katharina Helene Susek et al. Frontiers in Immunology
- NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines
- (2018) Nadine van Montfoort et al. CELL
- Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
- (2018) Pascale André et al. CELL
- Tumor Microenvironment-Induced Immunometabolic Reprogramming of Natural Killer Cells
- (2018) Andrea M. Chambers et al. Frontiers in Immunology
- The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex
- (2018) Caroline Jochems et al. OncoImmunology
- LAG3 (CD223) as a cancer immunotherapy target
- (2017) Lawrence P. Andrews et al. IMMUNOLOGICAL REVIEWS
- Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization
- (2017) Silvia Pesce et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity
- (2017) E Liu et al. LEUKEMIA
- IL-18/IL-15/IL-12 synergy induces elevated and prolonged IFN-γ production by ex vivo expanded NK cells which is not due to enhanced STAT4 activation
- (2017) Evan Lusty et al. MOLECULAR IMMUNOLOGY
- IL-1R8 is a checkpoint in NK cells regulating anti-tumour and anti-viral activity
- (2017) Martina Molgora et al. NATURE
- Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells
- (2017) Thorsten Gantke et al. PROTEIN ENGINEERING DESIGN & SELECTION
- The histone deacetylase inhibitor SAHA simultaneously reactivates HIV-1 from latency and up-regulates NKG2D ligands sensitizing for natural killer cell cytotoxicity
- (2017) Maria Giovanna Desimio et al. VIROLOGY
- Loss of Fas expression and high expression of HLA-E promoting the immune escape of early colorectal cancer cells
- (2017) Renxiang Huang et al. Oncology Letters
- IL-21-mediated reversal of NK cell exhaustion facilitates anti-tumour immunity in MHC class I-deficient tumours
- (2017) Hyungseok Seo et al. Nature Communications
- Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis
- (2017) Eva M. Putz et al. OncoImmunology
- IL-12, IL-15, and IL-18 pre-activated NK cells target resistant T cell acute lymphoblastic leukemia and delay leukemia development in vivo
- (2017) Margherita Boieri et al. OncoImmunology
- Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma
- (2017) Veronika Kremer et al. Journal for ImmunoTherapy of Cancer
- IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells
- (2016) Y. Mao et al. BLOOD
- Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells
- (2016) Dhifaf Sarhan et al. CANCER RESEARCH
- Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy
- (2016) S. J. Blake et al. CLINICAL CANCER RESEARCH
- NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
- (2016) D. H. Charych et al. CLINICAL CANCER RESEARCH
- IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function
- (2016) D. A. Vallera et al. CLINICAL CANCER RESEARCH
- Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma
- (2016) M. Carlsten et al. CLINICAL CANCER RESEARCH
- An Fc-optimized CD133 antibody for induction of NK cell reactivity against myeloid leukemia
- (2016) S P Koerner et al. LEUKEMIA
- Enhanced ADCC and NK Cell Activation of an Anticarcinoma Bispecific Antibody by Genetic Insertion of a Modified IL-15 Cross-linker
- (2016) Joerg U Schmohl et al. MOLECULAR THERAPY
- CIS is a potent checkpoint in NK cell–mediated tumor immunity
- (2016) Rebecca B Delconte et al. NATURE IMMUNOLOGY
- TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway
- (2016) Sébastien Viel et al. Science Signaling
- TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway
- (2016) Sébastien Viel et al. Science Signaling
- Phase I Study of Random Healthy Donor-Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors
- (2016) Y. Yang et al. Cancer Immunology Research
- Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia
- (2016) Emily M. McWilliams et al. OncoImmunology
- Inhibitory receptors as targets for cancer immunotherapy
- (2015) Meghan E. Turnis et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells
- (2015) L. Ruggeri et al. HAEMATOLOGICA
- The Clinical Significance of Abnormal Tim-3 Expression on NK Cells from Patients with Gastric Cancer
- (2015) Zhenxin Wang et al. IMMUNOLOGICAL INVESTIGATIONS
- Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma
- (2015) Liyun Xu et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer
- (2015) Kevin C. Conlon et al. JOURNAL OF CLINICAL ONCOLOGY
- B7H6-Specific Bispecific T Cell Engagers Lead to Tumor Elimination and Host Antitumor Immunity
- (2015) Ming-Ru Wu et al. JOURNAL OF IMMUNOLOGY
- Expression of immune checkpoint molecules of T cell immunoglobulin and mucin protein 3/galectin-9 for NK cell suppression in human gastrointestinal stromal tumors
- (2015) HIDEO KOMITA et al. ONCOLOGY REPORTS
- Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells
- (2015) L. Ruggeri et al. HAEMATOLOGICA
- Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models
- (2015) P. R. Rhode et al. Cancer Immunology Research
- The Shared and Contrasting Roles of IL2 and IL15 in the Life and Death of Normal and Neoplastic Lymphocytes: Implications for Cancer Therapy
- (2015) T. A. Waldmann Cancer Immunology Research
- IL-15–PI3K–AKT–mTOR: A Critical Pathway in the Life Journey of Natural Killer Cells
- (2015) Alaa Kassim Ali et al. Frontiers in Immunology
- Critical Role of Tumor Microenvironment in Shaping NK Cell Functions: Implication of Hypoxic Stress
- (2015) Meriem Hasmim et al. Frontiers in Immunology
- Therapeutic Potential and Challenges of Natural Killer Cells in Treatment of Solid Tumors
- (2015) Andrea Gras Navarro et al. Frontiers in Immunology
- Antibody Fc engineering improves frequency and promotes kinetic boosting of serial killing mediated by NK cells
- (2014) G. Romain et al. BLOOD
- CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets
- (2014) M. K. Gleason et al. BLOOD
- Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein
- (2014) V. Bachanova et al. BLOOD
- Valproic acid sensitizes pancreatic cancer cells to natural killer cell-mediated lysis by upregulating MICA and MICB via the PI3K/Akt signaling pathway
- (2014) Pengfei Shi et al. BMC CANCER
- CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo
- (2014) Erik Wennerberg et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Inhibition of Tumor-Derived Prostaglandin-E2 Blocks the Induction of Myeloid-Derived Suppressor Cells and Recovers Natural Killer Cell Activity
- (2014) Y. Mao et al. CLINICAL CANCER RESEARCH
- Effect of tumor cells and tumor microenvironment on NK-cell function
- (2014) Massimo Vitale et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide
- (2014) I. S. Nijhof et al. HAEMATOLOGICA
- A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma
- (2014) N. Korde et al. HAEMATOLOGICA
- IL-2: The First Effective Immunotherapy for Human Cancer
- (2014) S. A. Rosenberg JOURNAL OF IMMUNOLOGY
- The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions
- (2014) Christopher J Chan et al. NATURE IMMUNOLOGY
- Therapeutic vaccines for cancer: an overview of clinical trials
- (2014) Ignacio Melero et al. Nature Reviews Clinical Oncology
- Targeting CD20+ Aggressive B-cell Non-Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice
- (2014) Y. Chu et al. Cancer Immunology Research
- Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade
- (2014) I. P. da Silva et al. Cancer Immunology Research
- Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity
- (2014) Henri-Alexandre Michaud et al. OncoImmunology
- Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies
- (2013) H. E. Kohrt et al. BLOOD
- A novel inhibitor of proteasome deubiquitinating activity renders tumor cells sensitive to TRAIL-mediated apoptosis by natural killer cells and T cells
- (2013) Dhifaf Sarhan et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Immune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors
- (2013) S. Rusakiewicz et al. CANCER RESEARCH
- Targeting Natural Killer Cells to Acute Myeloid Leukemia In Vitro with a CD16 x 33 Bispecific Killer Cell Engager and ADAM17 Inhibition
- (2013) A. Wiernik et al. CLINICAL CANCER RESEARCH
- The Interleukin-1 Family: Back to the Future
- (2013) Cecilia Garlanda et al. IMMUNITY
- Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling
- (2013) Erik Wennerberg et al. INTERNATIONAL JOURNAL OF CANCER
- Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency
- (2013) Marie Vincent et al. INTERNATIONAL JOURNAL OF CANCER
- The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma
- (2013) Achim Rothe et al. INTERNATIONAL JOURNAL OF CANCER
- Rescue of Impaired NK Cell Activity in Hodgkin Lymphoma With Bispecific Antibodies In Vitro and in Patients
- (2013) Katrin S. Reiners et al. MOLECULAR THERAPY
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission
- (2012) N. Vey et al. BLOOD
- A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma
- (2012) D. M. Benson et al. BLOOD
- Cytokine activation induces human memory-like NK cells
- (2012) R. Romee et al. BLOOD
- A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies
- (2012) Noriko Shimasaki et al. CYTOTHERAPY
- Immunocytokines: a novel class of potent armed antibodies
- (2012) Nadine Pasche et al. DRUG DISCOVERY TODAY
- Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’
- (2012) Aron M. Levin et al. NATURE
- Bortezomib Treatment to Potentiate the Anti-tumor Immunity of Ex-vivo Expanded Adoptively Infused Autologous Natural Killer Cells
- (2012) Andreas Lundqvist et al. Journal of Cancer
- Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients
- (2011) A. Curti et al. BLOOD
- IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect
- (2011) D. M. Benson et al. BLOOD
- Heterodimeric bispecific antibody-derivatives against CD19 and CD16 induce effective antibody-dependent cellular cytotoxicity against B-lymphoid tumor cells
- (2011) Christian Kellner et al. CANCER LETTERS
- Human Breast Tumor Cells Induce Self-Tolerance Mechanisms to Avoid NKG2D-Mediated and DNAM-Mediated NK Cell Recognition
- (2011) E. Mamessier et al. CANCER RESEARCH
- Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression
- (2011) M. R. Parkhurst et al. CLINICAL CANCER RESEARCH
- Construction and humanization of a functional bispecific EGFR × CD16 diabody using a refolding system
- (2011) Ryutaro Asano et al. FEBS Journal
- The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
- (2010) D. M. Benson et al. BLOOD
- A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer
- (2010) Eleni G. Iliopoulou et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer
- (2010) Melissa A. Geller et al. CYTOTHERAPY
- Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells
- (2009) F. Romagne et al. BLOOD
- Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells
- (2009) A. Lundqvist et al. BLOOD
- Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method
- (2009) L Li et al. CANCER GENE THERAPY
- Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo
- (2009) C. Sola et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells
- (2008) Mareike Schmudde et al. CANCER LETTERS
- Permanent silencing of NKG2A expression for cell-based therapeutics
- (2008) Constança Figueiredo et al. JOURNAL OF MOLECULAR MEDICINE-JMM
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation